



**BIOSENSORS' DRUG-ELUTING STENT CONTINUES TO SHOW COMPARABLE
SAFETY AND EFFICACY TO INDUSTRY LEADING DRUG-ELUTING STENT
AND OUTPERFORMS CONTROL DEVICE IN SUB-STUDY**

Washington, DC, 13 October 2008 – Biosensors International Group, Ltd (“Biosensors”, or the “Company”, Bloomberg: BIG SP) released today additional results from its ground-breaking LEADERS clinical trial that continue to show equivalent safety and efficacy to the industry standard drug-eluting stent at 12 months. The results sustained the findings of the 9-month data released earlier this year. Biosensors’ drug-eluting stent is the first drug-eluting stent to demonstrate equivalent safety and efficacy to the industry standard drug-eluting stent in a large-scale, randomized, head-to-head non-inferiority trial. The company announced the 12-month results during the 2008 Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, DC.

In addition to the overall results, Biosensors also announced the results of a pre-defined sub-group analysis using optical coherence tomography (“OCT”), an advanced medical imaging technology, to directly compare post-implantation tissue coverage between the two stents. The sub-study, the first of its kind, showed that the Biosensors’ stent had a significantly higher degree of nearly-complete stent coverage than the comparison device. Uncovered stent struts may disrupt blood flow within the vessel and could be a contributing factor in stent thrombosis. Full details of the 12-month results and the subset analysis will be published separately.

LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) is a multi-centre, randomized study in which 1,707 patients eligible for percutaneous coronary intervention (“PCI”) for symptomatic coronary disease received either a Biosensors Biolimus-eluting drug-eluting stent with an abluminal biodegradable polymer coating, or a Cypher Sirolimus-eluting drug-eluting stent with a durable polymer. In total, 2,472 coronary lesions were treated. Inclusion criteria were broad, reflecting routine clinical practice, without limitations regarding type of coronary vessel, lesion length or number of treated lesions. Patient conditions known as “off-label indications”, including acute coronary syndromes, saphenous vein grafts and previously treated lesions were also included in the trial. The primary endpoint of the study was non-inferiority of the composite of cardiac death, myocardial infarction, and clinically-driven target vessel revascularization (“TVR”) at nine months follow-up.

Funded by Biosensors, LEADERS was independently developed, implemented and analyzed by the study investigators. Data management and analysis were performed by an independent academic institution. The 9-month results were published in a peer-reviewed article in the UK medical journal *The Lancet* in September 2008.

Media and Investor Relations Contact

Biosensors International Group
Mr. Loh Chee Mun
Tel: (65) 6213 5708
Email: cm.loh@biosensors.com

Media Relations / Investor Relations Firm

United States
Allen & Caron Inc.
Mr. Matt Clawson
Executive Vice President, Investor Relations
Tel: (1) 949 474 4300
Email: matt@allencaron.com

About Biosensors International Group, Ltd

Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug-eluting stents and has developed a pipeline of next-generation products that are set to gain market share from traditional therapies such as conventional drug-eluting stents, bare-metal stenting and open-heart surgery. It has two separate drug-eluting stent programs, *BioMatrix*TM and *BioFreedom*TM, a completely polymer-free drug-eluting stent.

For more information, please visit www.biosensors.com.

Forward-Looking Statements

Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward-looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.